They review common resistance mechanisms, such as secondary mutations (T790M, C797S), pathway activation, and histologic ...
Gibson's most famous moment came 37 years ago this month. Now he's leading another team towards a very different goal.
Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback